Skip to main content
eScholarship
Open Access Publications from the University of California

Specialty Drug Prices and the Medi-Cal Program

Abstract

Rising specialty drug costs pose a substantial problem for the California state budget and the problem will continue to grow. While these trends are of concern to all payers, this brief focuses on the implications for California’s Medicaid program, Medi-Cal, using the example of Sovaldi, a treatment for hepatitis C.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View